Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs market has been growing in Burkina Faso in recent years. This growth can be attributed to several factors.
Customer preferences: Anti-Fibrinolytic Drugs are used to prevent excessive bleeding during surgeries. The market for these drugs is primarily driven by hospitals and surgical centers. With an increase in the number of surgeries being performed in Burkina Faso, the demand for Anti-Fibrinolytic Drugs has also increased.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Burkina Faso is the rise in the number of surgeries being performed. This trend is expected to continue as the country's healthcare infrastructure improves. In addition, the use of generic drugs is also on the rise in Burkina Faso, which has led to an increase in the availability of Anti-Fibrinolytic Drugs at lower prices.
Local special circumstances: The healthcare system in Burkina Faso is still developing. The country faces a shortage of healthcare professionals, which has led to a lack of access to quality healthcare for many people. This has resulted in a higher demand for drugs that can prevent excessive bleeding during surgeries. In addition, Burkina Faso has a high incidence of diseases such as malaria and HIV, which can lead to complications during surgeries. Anti-Fibrinolytic Drugs are often used to prevent bleeding complications in such cases.
Underlying macroeconomic factors: Burkina Faso is one of the poorest countries in the world, with a low GDP per capita. However, the country has been experiencing stable economic growth in recent years. This has led to an increase in healthcare spending by the government, which has helped to improve the healthcare infrastructure in the country. In addition, Burkina Faso has a young population, which has resulted in a higher demand for healthcare services. This has contributed to the growth of the Anti-Fibrinolytic Drugs market in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
